Partial Remission in Pediatric Relapsed Neuroblastoma After Multiple Cycle Low-Dose 211 At-MABG Therapy.
Zitong Zhang, Hui Wang, Hongming Zhuang et al.
✦ AI-curated · Sources linked
Case in brief
An 11-year-old boy with relapsed, poorly differentiated left adrenal neuroblastoma and multiple bone metastases was treated with low-dose 211 At-MABG-targeted alpha therapy after failing prior multimodal therapy. Follow-up imaging showed resolution of most lesions and significantly reduced tracer uptake at the remaining site, leading to a decrease in his Curie score from 4 to 1.
Diagnostic / clinical pearl
This case illustrates the potential of low-dose 211 At-MABG-targeted alpha therapy in achieving partial remission in pediatric patients with relapsed neuroblastoma.
Why it matters
The findings support the feasibility and safety of this therapeutic approach, which may offer new options for managing relapsed neuroblastoma in children.